Frontiers in Drug Design and Discovery

Volume 8

by

Atta-ur-Rahman, M. Iqbal Choudhary

DOI: 10.2174/97816810835511170801
eISBN: 978-1-68108-355-1, 2017
ISBN: 978-1-68108-356-8
ISSN: 1574-0889 (Print)
ISSN: 2212-1064 (Online)



Recommend this eBook to your Library



Frontiers in Drug Design and Discovery is a book series devoted to publishing t...[view complete introduction]

Table of Contents

Preface

- Pp. i-ii (2)

Atta-ur-Rahman and M. Iqbal Choudhary

Download Free

List of Contributors

- Pp. iii-iv (2)

Atta-ur-Rahman

Download Free

Cancer Chemotherapy: Recent Developments in Hematology Oncology

- Pp. 1-51 (51)

Sapna Parmar, Rebecca Nelson and Erica Hochard

View Abstract Purchase Chapter

Current Innovations in Management of Esophageal Carcinoma

- Pp. 52-133 (82)

Julie H. Rowe, Fathima Kamil, Melissa Yan, Curtis J. Wray and Atilla Ertan

View Abstract Purchase Chapter

Androgen Deprivation Therapy for Prostate Cancer

- Pp. 134-171 (38)

Patricia Tai, Evgeny Sadikov, Asim Amjad, Nelson Leong, Arbind Dubey, Wojciech Dolata, Miroslav Jancewicz and Rashmi Koul

View Abstract Purchase Chapter

Cancer and its Treatment: Development of Anticancer Chemotherapeutic Agents from Natural Products

- Pp. 172-241 (70)

S. K. Mishra, S. Tiwari, A. A. Mahdi, S. K. Agarwal and V. Lakshmi

View Abstract Purchase Chapter

Polyhydroxyalkanoates as Promising Materials in Biomedical Systems

- Pp. 242-288 (47)

Michał Michalak, Sebastian Jurczyk, Katarzyna Jelonek, Minna Hakkarainen and Piotr Kurcok

View Abstract Purchase Chapter

Subject Index

- Pp. 289-297 (9)

Atta-ur-Rahman

Download Free

Preface

Drug discovery and development against prevailing and emerging diseases is one of the most important areas of modern health care research. This interdisciplinary area requires consistent well coordinated efforts of scientists with diverse expertise. It starts from target identification that underlies a particular disease process. It often takes years of study in order to characterize the targets for a potential drug. Once a receptor target has been characterized and validated, the most challenging task of identifying appropriate ligands from natural or synthetic sources begins. The study of the biochemical mechanism of the receptor-ligand interaction is the next step in this process. Often the ligands need to be modified to achieve greater specificity and affinity, requiring skills of medicinal chemists. This is followed by pre-clinical and clinical studies for safety, efficacy and specificity, often leading to frustrating failures, and re-initiation of the whole process. Finally, there are other considerations in the development of new drugs, termed ADMET (absorption, desorption, metabolism, excretion, and toxicity). Despite the challenges associated with the drug discovery and development, it is a fascinating and much needed scientific research which continues unabated.

The 8th volume of the ebook series entitled, “Frontiers in Drug Design and Discovery”, is a compilation of five exhaustively written reviews focussing on various aspects of drug discovery and development in key therapeutic areas. These reviews provide a wealth of information about topics of great interest in this field.

Parmer et al., have contributed a comprehensive review on the development of new chemotherapautic agents against haematological cancers. Hematological malignancies are among the most common cancer types. They affect the blood and lymph systems and include chronic and acute leukaemia, non-Hodgkin lymphoma, Hodgkin lymphoma, and multiple myeloma. There has been a major gap between the needs of treatment for haematological cancers and the current pace of drug development in this field. The authors have skilfully dealt with the subject by highlighting major developments in this important area along with pharmacology, pharmacokinetics, and clinical studies on various classes of drugs, including targeted therapies.

In chapter 2, Rowe et al. review the recent literature on the current developments in the management of esophageal carcinoma. The review begins with the description of two major types of esophageal carcinoma i.e. squamous cell carcinoma and adenocarcinoma. Different therapeutic interventions at various stages of esophageal carcinoma, as well as the health status and age of patients are described. This review presents treatment options for squamous cell cancer such as chemotherapy and radiation therapy as the first lines of treatment followed by surgery. Studies showing that chemoradiotherapy before surgery is better than surgery alone are presented. For adenocarcinoma, the most common treatment is chemotherapy and radiation therapy, followed by surgery. For advanced stage esophageal cancer, chemotherapy and radiation therapy remain the only options. Most importantly, the review describes advances in endoscopic treatments of early stage esophageal cancers such as endoscopic mucosal resection (EMR), endoscopic submucosal dissection (ESD) as well as endoscopic ablation procedures, including photodynamic therapy (PDT) and radio frequency ablation (RFA). These advances have proven to be safe and effective for the treatment of esophageal dysplasia and early stage neoplasia.

Androgen hormones stimulate prostate cancer cells to grow faster. The most important among them are testosterone and dihydrotestosterone (DHT). Lowering androgen levels or stopping them from getting into prostate cancer cells have been used to slow down the growth of prostate cancers. This is called androgen deprivation therapy (ADT). However, there are a lot of controversies associated with ADT. Tai et al in chapter 3 have reviewed past uses, and recent scientific evidences concerning the ADT in the treatment of prostate cancer. Current trends of the use of ADT in combination with radiotherapy to avoid recurrence of cancer are discussed.

Secondary metabolites from natural sources such as plants, microorganisms, and marine organisms have played an important role in world’s healthcare systems from ancient times till to date. Many cancer chemotherapeutic drugs have been obtained from nature and modified for optimal activity and safety. As cancers continue to take heavy toll of human life, the search for natural products with anti-neoplastic activities has continued in recent years with large scale screenings of marine fauna and flora, terrestrial microorganisms and plants in many laboratories of the world. Several new classes of natural products and their derivatives have been developed with the potential to be used as cancer chemotherapeutic agents. Lakshmi et al. comprehensively review the most notable discoveries of anti-cancer natural products in the last 5 decades in chapter 4. Most importantly, they describe the mechanism of action of key classes of natural anti-cancer agents at molecular levels, such as inhibition of enzymes and signalling pathways. The structure-activity relationships and results of pre-clinical studies add further value to this chapter.

Finally, chapter 5 by Kurcok et al is focussed on the tremendous new and well known biomedical and pharmaceutical applications of natural biopolymers, polyhydroxyalkanoates (PHAs). These natural linear polyesters are produced intercellularly by various species of bacteria through the fermentation of sugars or lipids. Many PHAs have also been prepared by chemical synthesis. PHAs are generally biocompatible and biodegradable in nature, and are used in the production of bioplastics. PHAs and their copolymers have found extensive applications in biomedical systems, including tissue engineering, orthopaedic materials, drug-loaded implants, drug careers, transdermal administration drugs and cosmetics, etc. Recent research studies on the conjugation of drugs with low molecular weight PHAs have shown to improve the bioavailability and safety profiles of drugs.

The above chapters are contributed by leading researchers and experts in the fields making volume 8 of the Frontiers in Drug Design and Discovery an interesting and useful reading for both young and established scientists, as well as students of biomedical and health sciences, and medicinal and pharmaceutical chemistry. We wish to express our gratitude to them for their excellent scholarly contributions for this reputed ebook series. We also greatly appreciate the efforts of the entire team of Bentham Science Publishers for efficient and timely processing of the publication. The skills, efforts and commitment of Mr. Omer Shafi (Assistant Manager Publications), Mr. Shehzad Naqvi (Manager Publications) and leadership of Mr. Mahmood Alam (Director Publications) are especially praiseworthy. We also hope that like the previous volumes of this internationally recognized book series, volume 8 will also receive wide readership, and appreciation.

Atta-ur-Rahman, FRS
Kings College,
University of Cambridge,
Cambridge,
UK
&
M. Iqbal Choudhary
H.E.J. Research Institute of Chemistry,
International Center for Chemical and Biological Sciences,
University of Karachi,
Karachi,
Pakistan

List of Contributors

Editor(s):
Atta-ur-Rahman FRS
Honorary Life Fellow
Kings College
University of Cambridge
UK


M. Iqbal Choudhary
H.E.J. Research Institute of Chemistry
University of Karachi
Karachi-75270
Pakistan




Contributor(s):
A.A. Mahdi
Department of Biochemistry
King George’s Medical University
Lucknow 226001
India


Arbind Dubey
Departments of Radiation Oncology (PT, ES, AA, NL), and Medical Oncology (WD, MJ)
Allan Blair Cancer Centre
Regina
Saskatchewan
Canada
/
Department of Radiation Oncology (AD, RK)
CancerCare Manitoba
Winnipeg
Manitoba
Canada


Asim Amjad
Departments of Radiation Oncology (PT, ES, AA, NL), and Medical Oncology (WD, MJ)
Allan Blair Cancer Centre
Regina
Saskatchewan
Canada
/
Department of Radiation Oncology (AD, RK)
CancerCare Manitoba
Winnipeg
Manitoba
Canada


Atilla Ertan
University of Texas Health Science Center-McGovern Medical School
Houston
Texas
USA
/
Department of Internal Medicine, Division of Gastroenterology, Hepatology, and Nutrition
University of Texas Health Science Center
Houston
Texas
USA


Curtis J. Wray
University of Texas Health Science Center-McGovern Medical School
Houston
Texas
USA
/
Department of Surgery, Division of Minimally Invasive and Elective General Surgery
University of Texas Health Science Center
Street no.
Houston
Texas
USA


Erica Hochard
NewYork-Presbyterian Hospital/Weill Cornell Medical Center
New York
NY
USA


Evgeny Sadikov
Departments of Radiation Oncology (PT, ES, AA, NL), and Medical Oncology (WD, MJ)
Allan Blair Cancer Centre
Regina
Saskatchewan
Canada
/
Department of Radiation Oncology (AD, RK)
CancerCare Manitoba
Winnipeg
Manitoba
Canada


Fathima Kamil
University of Texas Health Science Center-McGovern Medical School
Houston
Texas
USA
/
Department of Internal Medicine
University of Texas Health Science Center
Houston
Texas
USA


Julie H. Rowe
University of Texas Health Science Center-McGovern Medical School
Houston
Texas
USA
/
Department of Internal Medicine, Division of Oncology
University of Texas Health Science Center
Houston
Texas
USA


Katarzyna Jelonek
Centre of Polymer and Carbon Materials
Polish Academy of Sciences
34, M. Curie-Skłodowskiej St.
41-819 Zabrze
Poland


Melissa Yan
University of Texas Health Science Center-McGovern Medical School
Houston
Texas
USA
/
Department of Internal Medicine
University of Texas Health Science Center
Houston
Texas
USA


Michał Michalak
Centre of Polymer and Carbon Materials
Polish Academy of Sciences
34, M. Curie-Skłodowskiej St.
41-819 Zabrze
Poland


Minna Hakkarainen
Department of Fibre and Polymer Technology
KTH Royal Institute of Technology
Stockholm
Sweden


Miroslav Jancewicz
Departments of Radiation Oncology (PT, ES, AA, NL), and Medical Oncology (WD, MJ)
Allan Blair Cancer Centre
Regina
Saskatchewan
Canada
/
Department of Radiation Oncology (AD, RK)
CancerCare Manitoba
Winnipeg
Manitoba
Canada


Nelson Leong
Departments of Radiation Oncology (PT, ES, AA, NL), and Medical Oncology (WD, MJ)
Allan Blair Cancer Centre
Regina
Saskatchewan
Canada
/
Department of Radiation Oncology (AD, RK)
CancerCare Manitoba
Winnipeg
Manitoba
Canada


Patricia Tai
Departments of Radiation Oncology (PT, ES, AA, NL), and Medical Oncology (WD, MJ)
Allan Blair Cancer Centre
Regina
Saskatchewan
Canada
/
Department of Radiation Oncology (AD, RK)
CancerCare Manitoba
Winnipeg
Manitoba
Canada


Piotr Kurcok
Centre of Polymer and Carbon Materials
Polish Academy of Sciences
34, M. Curie-Skłodowskiej St.
41-819 Zabrze
Poland
/
Institute of Chemistry, Environment Protection and Biotechnology
Jan Długosz Academy
13/15 Armii Krajowej Ave.
42-200 Czestochowa
Poland


Rashmi Koul
Departments of Radiation Oncology (PT, ES, AA, NL), and Medical Oncology (WD, MJ)
Allan Blair Cancer Centre
Regina
Saskatchewan
Canada
/
Department of Radiation Oncology (AD, RK)
CancerCare Manitoba
Winnipeg
Manitoba
Canada


Rebecca Nelson
NewYork-Presbyterian Hospital/Weill Cornell Medical Center
New York
NY
USA


S. Tiwari
Pesticide Toxicology Division
Indian Institute of Toxicology Research
Lucknow 226001
India


S.K. Agarwal
Department of Biochemistry
King George’s Medical University
Lucknow 226001
India


S.K. Mishra
Medicinal and Process Chemistry Division
Central Drug Research Institute
Lucknow 226001
India


Sapna Parmar
NewYork-Presbyterian Hospital/Weill Cornell Medical Center
New York
NY
USA


Sebastian Jurczyk
Paint and Plastics Department in Gliwice
Institute for Engineering of Polymer Materials and Dyes
50A Chorzowska St.
44-100 Gliwice
Poland


V. Lakshmi
Medicinal and Process Chemistry Division
Central Drug Research Institute
Lucknow 226001
India
/
Department of Biochemistry
King George’s Medical University
Lucknow 226001
India


Wojciech Dolata
Departments of Radiation Oncology (PT, ES, AA, NL), and Medical Oncology (WD, MJ)
Allan Blair Cancer Centre
Regina
Saskatchewan
Canada
/
Department of Radiation Oncology (AD, RK)
CancerCare Manitoba
Winnipeg
Manitoba
Canada




Advertisement



Webmaster Contact: info@benthamscience.org Copyright © 2017 Bentham Science